Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALANASDAQ:CHMANASDAQ:FTSVNASDAQ:KMDANASDAQ:MRKR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.03-28.5%$0.02$0.01▼$0.50$122K-0.171,607 shs1,075 shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AKMDAKamada$5.10+0.4%$5.78$4.08▼$6.53$293.10M1.0423,627 shs6,510 shsMRKRMarker Therapeutics$4.10-4.9%$4.26$0.76▼$9.68$36.49M1.521,056 shs13,050 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences-20.00%+100.00%+100.00%+28.00%-23.08%CHMAChiasma0.00%0.00%0.00%0.00%0.00%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%KMDAKamada+3.67%-3.61%-13.46%-13.61%+8.32%MRKRMarker Therapeutics-2.05%-11.13%-0.23%-0.46%+302.80%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.1185 of 5 stars3.55.00.00.02.71.73.1MRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera BiosciencesN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AKMDAKamada3.00Buy$11.00115.69% UpsideMRKRMarker TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest KMDA, MRKR, FTSV, CALA, and CHMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.06CHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70KMDAKamada$142.52M2.06$0.44 per share11.49$4.25 per share1.20MRKRMarker Therapeutics$3.31M11.02N/AN/A$1.58 per share2.60Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/AFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AKMDAKamada$8.28M$0.1534.0012.44N/A5.81%5.66%3.57%5/22/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)Latest KMDA, MRKR, FTSV, CALA, and CHMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ACHMAChiasmaN/A7.917.08FTSVForty SevenN/A14.8114.81KMDAKamadaN/A3.431.64MRKRMarker TherapeuticsN/A5.575.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACHMAChiasma61.68%FTSVForty Seven71.77%KMDAKamada20.38%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CHMAChiasma8.30%FTSVForty Seven37.40%KMDAKamada36.10%MRKRMarker Therapeutics24.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCHMAChiasma8557.89 millionN/ANot OptionableFTSVForty Seven5748.16 millionN/ANot OptionableKMDAKamada37857.47 million36.73 millionOptionableMRKRMarker Therapeutics678.90 million6.76 millionNot OptionableKMDA, MRKR, FTSV, CALA, and CHMA HeadlinesSourceHeadlineVolunteers needed for National Historic Marker Dayromesentinel.com - April 16 at 11:03 AMJennett Marker Named Human Resources Manager For Chore-Timetimesuniononline.com - April 13 at 7:52 AMHaliwa-Saponi Indian Tribe to be featured on Highway Historical Markerwarrenrecord.com - April 11 at 12:59 PMMarker Therapeutics Inc (MRKR)investing.com - April 10 at 8:50 PMWin an overnight stay with afternoon tea at Anantara The Marker Dublin Hotel.irishtimes.com - April 10 at 3:36 AMMicroRNA Liquid Biopsy Test Shows Potential for Early Pancreatic Cancer Detectionprecisionmedicineonline.com - April 9 at 5:13 PMPutnam Marker Honoring Warner Sisters Restored At Foundry Point Parkmsn.com - April 9 at 5:13 PMSite of former Allentown State Hospital to receive Official State Historical Markerwfmz.com - April 9 at 5:13 PMRobert Edgar Sherrill Memorial Marker Will Be Dedicated April 25chattanoogan.com - April 9 at 12:13 PMCinco de Mayo Margarita Battle at The Marker Key West Harbor Resortbocaratonobserver.com - April 9 at 12:13 PMPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignanciesglobenewswire.com - April 8 at 7:00 AMVolunteers needed April 26 for National Historic Marker Daywestsidenewsny.com - April 7 at 1:24 PMMorrisound Recording Awarded Historical Marker For Contributions To Extreme Metal, Music Industrymetalinjection.net - April 3 at 2:36 PMGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular Diseasesfinance.yahoo.com - April 3 at 2:36 PMMouse Models and Markers for Cerebral Amyloid Angiopathy, ARIAalzforum.org - March 28 at 5:52 PMThe Andy Westcott Band Concert at The Marker Key West Harbor Resortbocaratonobserver.com - March 27 at 9:34 AMMiddle Passage Marker in Port Arthur commemorates ancestors, provides history of local slave tradepanews.com - March 26 at 5:22 AMMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31Mmsn.com - March 26 at 5:22 AMMarker Therapeutics Reports Year-End 2023 Corporate and Financial Resultsglobenewswire.com - March 25 at 5:45 PMLegends & Lore Marker program accepting grant applicationsthedailynewsonline.com - March 23 at 2:55 AMMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conferenceglobenewswire.com - March 22 at 12:30 PMJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party Leadermsn.com - March 22 at 3:03 AMMarker dedication reset for Temple cemeterytdtnews.com - March 20 at 8:51 PMSpring Break Pool Party with DJ BUGGY at The Markerbocaratonobserver.com - March 19 at 3:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCalithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.ChiasmaNASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Forty SevenNASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.